A Promising Drug Candidate For Both Alzheimer’s And Parkinson’s Disease Could Drive This Surging Biotech Even Higher

The biotech featured in today’s article, focused on a new scientific approach to tackling Alzheimer’s disease and other neurodegenerative disorders, is up 884% so far this year thanks to promising trial results for its lead candidate in regards to Alzheimer’s and Parkinson’s disease – and with more data readouts expected in the coming weeks before the drug trial concludes in August, the stock could be poised to surge even higher. For more, CLICK HERE.